
    
      This is a phase II study. Patients with resectable pancreatic carcinoma will receive adjuvant
      chemotherapy of FOLFIRINOX for 6 months.

      Primary endpoint is the disease free survival. Secondary endpoints are overall survival,
      safety and quality of life.
    
  